The present invention provides a nitric-oxide containing composite in the form of microparticles, wherein said microparticles comprise: (i) a core which comprises silica; (ii) a layer on said core which comprises a metal-organic framework; and (iii) nitric oxide;
wherein said metal-organic framework comprises organic ligands comprising at least one amine group, said metal-organic framework is uniformly distributed on the surface of said silica core and said nitric oxide is chemisorbed within said metal-organic framework.

One compound (100) according to the present invention contains silicon fine particles having a capability of generating hydrogen or aggregates of the silicon fine particles. The compound that contains the silicon fine particles or the aggregates having a capability of generating hydrogen is capable of generating hydrogen in the body of, for example, an animal that has ingested the compound. For a plant, the compound can be disposed or charged into, for example, moisture (water-containing liquid) or fertilizer to be provided to the plant, to supply the plant with hydrogen generated from the compound.

Systems, products, compounds and methods can be applied and/or used by a person to facilitate and promote the production of nitric oxide to be used by a person for health benefits. The systems, products, and devices include a nitric oxide nasal delivery system. The system can comprise one or more containers for compounds that when mixed are adapted to produce nitric oxide gas, at least one container with a nitrite compound and at least one container with an acid compound. Containers can be ruptured so that the compounds may be mixed and produce nitric oxide gas. The nitric oxide gas may then be delivered to a user via one or more of the nasal cavities and/or mouth.

Systems, products, compounds and methods can be applied and/or used by a person to facilitate and promote the production of nitric oxide to be used by a person for health benefits. The systems, products, and devices include a nitric oxide nasal delivery system. The system can comprise one or more containers for compounds that when mixed are adapted to produce nitric oxide gas, at least one container with a nitrite compound and at least one container with an acid compound. Containers can be ruptured so that the compounds may be mixed and produce nitric oxide gas. The nitric oxide gas may then be delivered to a user via one or more of the nasal cavities and/or mouth.

Provided is a composition for treating and/or preventing cognitive impairment or dementia. The composition for treating and/or preventing cognitive impairment or dementia containing hydrogen gas, wherein the composition is used to allow the hydrogen gas to be inhaled by a subject. The concentration of the hydrogen gas to be inhaled is, for example, 0.5 to 18.3 vol %. The concentration of the hydrogen gas to be inhaled is, for example, 1 to 10 vol %. For example, the time of inhalation of the hydrogen gas is at least 10 minutes or longer per inhalation, and the frequency of inhalation of the hydrogen gas is once or more per day.

Provided is a composition for treating and/or preventing cognitive impairment or dementia. The composition for treating and/or preventing cognitive impairment or dementia containing hydrogen gas, wherein the composition is used to allow the hydrogen gas to be inhaled by a subject. The concentration of the hydrogen gas to be inhaled is, for example, 0.5 to 18.3 vol %. The concentration of the hydrogen gas to be inhaled is, for example, 1 to 10 vol %. For example, the time of inhalation of the hydrogen gas is at least 10 minutes or longer per inhalation, and the frequency of inhalation of the hydrogen gas is once or more per day.

A vitamin for use by kidney patients in Stages 3, 4, 4a, 4b, and 5, who are not on dialysis, comprising administering daily a: low nitrogen diet; low nitrogen protein food comprising magnesium and/or calcium salts of alpha keto acids; and time released vitamin. The vitamin comprises the active ingredients of: Zinc; Selenium; Vitamins B1, B2, B6, B12, B5, E, and K2; Niacin; superoxide dismutase; catalase; glutathione and Folate; and excludes calcium, magnesium, phosphorus, sodium, manganese, fluoride, Vitamin D and K1. The low nitrogen food contains daily up to 300 mg of nitrogen; and at least five alpha keto analogues of magnesium and/or calcium salts of: leucine, isoleucine, methionine (MEMS-II), phenylalanine (PAMS-I), and valine. Methods of making and the chemical structures MEMS-II and the PAMS-I are disclosed. The treatment results in an increase of Glomerular Filtration Rate (GFR), a decrease in blood urea levels, and a decrease in creatinine levels.

A vitamin for use by kidney patients in Stages 3, 4, 4a, 4b, and 5, who are not on dialysis, comprising administering daily a: low nitrogen diet; low nitrogen protein food comprising magnesium and/or calcium salts of alpha keto acids; and time released vitamin. The vitamin comprises the active ingredients of: Zinc; Selenium; Vitamins B1, B2, B6, B12, B5, E, and K2; Niacin; superoxide dismutase; catalase; glutathione and Folate; and excludes calcium, magnesium, phosphorus, sodium, manganese, fluoride, Vitamin D and K1. The low nitrogen food contains daily up to 300 mg of nitrogen; and at least five alpha keto analogues of magnesium and/or calcium salts of: leucine, isoleucine, methionine (MEMS-II), phenylalanine (PAMS-I), and valine. Methods of making and the chemical structures MEMS-II and the PAMS-I are disclosed. The treatment results in an increase of Glomerular Filtration Rate (GFR), a decrease in blood urea levels, and a decrease in creatinine levels.

A low nitrogen protein food composition Albutrix™ for use by kidney patients in Stages 3, 4, 4a, 4b, and 5, who are not on dialysis, in a treatment program comprising administering daily a: low nitrogen diet; low nitrogen protein food comprising magnesium and/or calcium salts of alpha keto acids; and time released vitamin. The vitamin comprises the active ingredients of: Zinc; Selenium; Vitamins B1, B2, B6, B12, B5, E, and K2; Niacin; superoxide dismutase; catalase; glutathione and Folate; and excludes calcium, magnesium, phosphorus, sodium, manganese, fluoride, Vitamin D and K1. The low nitrogen food contains daily up to 300 mg of nitrogen; and at least five alpha keto analogues of magnesium and/or calcium salts of: leucine, isoleucine, methionine (MEMS-II), phenylalanine (PAMS-I), and valine. The treatment results in an increase of Glomerular Filtration Rate (GFR), a decrease in blood urea levels, and a decrease in creatinine levels.

A low nitrogen protein food composition Albutrix™ for use by kidney patients in Stages 3, 4, 4a, 4b, and 5, who are not on dialysis, in a treatment program comprising administering daily a: low nitrogen diet; low nitrogen protein food comprising magnesium and/or calcium salts of alpha keto acids; and time released vitamin. The vitamin comprises the active ingredients of: Zinc; Selenium; Vitamins B1, B2, B6, B12, B5, E, and K2; Niacin; superoxide dismutase; catalase; glutathione and Folate; and excludes calcium, magnesium, phosphorus, sodium, manganese, fluoride, Vitamin D and K1. The low nitrogen food contains daily up to 300 mg of nitrogen; and at least five alpha keto analogues of magnesium and/or calcium salts of: leucine, isoleucine, methionine (MEMS-II), phenylalanine (PAMS-I), and valine. The treatment results in an increase of Glomerular Filtration Rate (GFR), a decrease in blood urea levels, and a decrease in creatinine levels.